EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy

Shunzhe Zheng, Guanting Li, Jianbin Shi, Xinying Liu, Meng Li, Zhonggui He, Chutong Tian, Ken-Ichiro Kamei

Journal of Controlled Release · 2023-09 · 361 · 819-846

DOI: 10.1016/j.jconrel.2023.08.035 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2023-09. Verfasst von Shunzhe Zheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 409 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Owing to the unique DNA damaging cytotoxicity, platinum (Pt)-based chemotherapy has long been the first-line choice for clinical oncology. Unfortunately, Pt drugs are restricted by the severe dose-dependent toxicity and drug resistance. Correspondingly, Pt(IV) prodrugs are developed with the aim to improve the antitumor performance of Pt drugs. However, as "free" molecules, Pt(IV) prodrugs are still subject to unsatisfactory in vivo destiny and antitumor efficacy. Recently, Pt(IV) prodrug nanotherapeutics, inheriting both the merits of Pt(IV) prodrugs and nanotherapeutics, have emerged and demonstrated the promise to address the underexploited dilemma of Pt-based cancer therapy. Herein, we summarize the latest fronts of emerging Pt(IV) prodrug nanotherapeutics. First, the basic outlines of Pt(IV) prodrug nanotherapeutics are overviewed. Afterwards, how versatile Pt(IV) prodrug nanotherapeutics overcome the multiple biological barriers of antitumor drug delivery is introduced in detail. Moreover, advanced combination therapies based on multimodal Pt(IV) prodrug nanotherapeutics are discussed with special emphasis on the synergistic mechanisms. Finally, prospects and challenges of Pt(IV) prodrug nanotherapeutics for future clinical translation are spotlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNeoplasmsHumansCombined Modality TherapyDrug Delivery SystemsMedical OncologyPlatinum

Stichwörter der Autor:innen

Cancer therapyCombination therapyPlatinum drugPlatinum(IV) prodrugProdrug nanotherapeutics

Substanzen

ProdrugsPlatinum

Autor:innen und Institutionen

  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, Hangzhou 310058, China. Electro…
  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto 606-8501, Japan.…

Zitieren

APA

Zheng, S., Li, G., Shi, J., Liu, X., Li, M., He, Z., Tian, C., & Kamei, K. I. (2023). Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy. Journal of Controlled Release, 361, 819-846. https://doi.org/10.1016/j.jconrel.2023.08.035

Vancouver

Zheng S, Li G, Shi J, Liu X, Li M, He Z, et al. Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy. Journal of Controlled Release. 2023;361:819-846. doi:10.1016/j.jconrel.2023.08.035

BibTeX
@article{Zheng2023,
  author = {Zheng, Shunzhe and Li, Guanting and Shi, Jianbin and Liu, Xinying and Li, Meng and He, Zhonggui and Tian, Chutong and Kamei, Ken-Ichiro},
  title = {Emerging platinum(IV) prodrug nanotherapeutics: A new epoch for platinum-based cancer therapy},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {361},
  pages = {819--846},
  doi = {10.1016/j.jconrel.2023.08.035}
}
Kostenlos starten →